2017
Mecamylamine treatment for alcohol dependence: a randomized controlled trial
Petrakis IL, Ralevski E, Gueorguieva R, O'Malley SS, Arias A, Sevarino KA, Jane JS, O'Brien E, Krystal JH. Mecamylamine treatment for alcohol dependence: a randomized controlled trial. Addiction 2017, 113: 6-14. PMID: 28710873, PMCID: PMC5725262, DOI: 10.1111/add.13943.Peer-Reviewed Original ResearchConceptsHeavy drinking daysDrinking daysAlcohol use disorderUse disordersAlcohol consumptionAlcohol dependenceDouble-blind clinical trialNicotinic acetylcholine receptor antagonistWeeks of treatmentAcetylcholine receptor antagonistCurrent alcohol dependenceSignificant differencesTreatment-seeking smokersMecamylamine treatmentPlacebo groupMonth 3Primary outcomeSmoking statusNicotine withdrawalReceptor antagonistNovel pharmacotherapiesClinical trialsManagement therapyMecamylamineTreatment groups
2011
Effects of Acamprosate on Cognition in a Treatment Study of Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence
Ralevski E, O'Brien E, Jane JS, Dean E, Dwan R, Petrakis I. Effects of Acamprosate on Cognition in a Treatment Study of Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence. The Journal Of Nervous And Mental Disease 2011, 199: 499-505. PMID: 21716064, DOI: 10.1097/nmd.0b013e3182214297.Peer-Reviewed Original ResearchConceptsCognitive functioningSchizophrenia spectrum disordersSpectrum disorderAlcohol dependenceComorbid alcohol dependencePsychotic symptomsSymptoms of psychosisCognitionEffects of acamprosateAlcohol useFunctioningTreatment studiesAlcohol reductionMemorySample of patientsAcamprosate treatmentGroup of patientsNegative effectsAlcohol consumptionDisordersAttentionSymptomsAcamprosatePatientsSchizophrenia